| アブストラクト | OBJECTIVE: This study aimed to compare the rates of urinary tract infections (UTIs) and fungal infections associated with metformin, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, and their combination. MATERIALS AND METHODS: We collected data on UTIs and fungal infections related to metformin, SGLT-2 inhibitors, and their combinations from the FDA Adverse Event Reporting System (FAERS) database. We calculated the reporting odds ratio (ROR) and 95% confidence intervals (CI) to assess the risk associated with these adverse events when using these medications. We evaluated differences in categorical variables using the Chi-squared test. RESULTS: SGLT-2 inhibitors present a higher risk of UTIs and fungal infections compared to metformin. Empagliflozin showed the lowest risk of UTIs (ROR 0.928, 95% CI 0.858-1.005), while dapagliflozin exhibited the lowest risk of fungal infections (ROR 0.874, 95% CI 0.815-0.938). Additionally, patients using SGLT-2 inhibitors alone reported more cases of UTIs and fungal infections than those treated with a combination of SGLT-2 inhibitors and metformin (ROR>1). CONCLUSION: SGLT-2 inhibitors are associated with an increased risk of UTIs and fungal infections compared to combination therapy with an SGLT-2 inhibitor and metformin. The reduced infection reports with combined SGLT-2 inhibitors and metformin therapy may be due to the potential antimicrobial activity of metformin. |
|---|
| ジャーナル名 | Journal of clinical practice and research |
|---|
| Pubmed追加日 | 2024/6/5 |
|---|
| 投稿者 | Aksoyalp, Zinnet Sevval; Temel, Aybala |
|---|
| 組織名 | Department of Pharmacology, Izmir Katip Celebi University Faculty of Pharmacy,;Izmir, Turkiye.;Department of Pharmaceutical Microbiology, Izmir Katip Celebi University Faculty;of Pharmacy, Izmir, Turkiye. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41613512/ |
|---|
